170 related articles for article (PubMed ID: 24754789)
1. Evaluation of the validity of Hb A2 and mean corpuscular haemoglobin action values in antenatal screening for beta thalassaemia carriers in England.
Daniel Y; Cartwright R; Rennie K; Streetly A; Howard J
Br J Haematol; 2014 Aug; 166(4):607-11. PubMed ID: 24754789
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the effect of three β-thalassemia prenatal screening strategies using in Guangdong province].
Li B; Yin A; Luo M; Wu L; Ma Y; Wang X; Zhang X; Zhao Q
Zhonghua Fu Chan Ke Za Zhi; 2015 Jun; 50(6):434-40. PubMed ID: 26311551
[TBL] [Abstract][Full Text] [Related]
3. Effects of α-thalassaemia mutations on the haematological parameters of β-thalassaemia carriers.
Saleh-Gohari N; Khademi Bami M; Nikbakht R; Karimi-Maleh H
J Clin Pathol; 2015 Jul; 68(7):562-6. PubMed ID: 25935548
[TBL] [Abstract][Full Text] [Related]
4. [The value of MCV, MCH and HbA(2) in laboratory screening of thalassemia].
Li LY; Li Q; Song LL; Jin WJ; Ma ZH; Yu YH; Zhong M
Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):96-100. PubMed ID: 22455739
[TBL] [Abstract][Full Text] [Related]
5. Effective screening for double heterozygosity of Hb E/alpha0-thalassemia.
Sanchaisuriya K; Chirakul S; Srivorakun H; Fucharoen G; Fucharoen S; Changtrakul Y; Sanchaisuriya P
Ann Hematol; 2008 Nov; 87(11):911-4. PubMed ID: 18575861
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of mean corpuscular hemoglobin (MCH): for screening alpha-thalassemia-1 trait and beta-thalassemia trait.
Pranpanus S; Sirichotiyakul S; Srisupundit K; Tongsong T
J Med Assoc Thai; 2009 Jun; 92(6):739-43. PubMed ID: 19530577
[TBL] [Abstract][Full Text] [Related]
7. Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of beta-thalassaemia trait.
Garner C; Dew TK; Sherwood R; Rees D; Thein SL
Br J Haematol; 2003 Oct; 123(2):353-8. PubMed ID: 14531920
[TBL] [Abstract][Full Text] [Related]
8. Haematological and electrophoretic characterisation of β-thalassaemia in Yunnan province of Southwestern China.
Zhang J; He J; Mao X; Zeng X; Chen H; Su J; Zhu B
BMJ Open; 2017 Jan; 7(1):e013367. PubMed ID: 28143837
[TBL] [Abstract][Full Text] [Related]
9. Effect of antiretroviral therapy on hemoglobin A2 values can have implications in antenatal beta-thalassemia screening programs.
Bhagat P; Kaur Sachdeva R; Sharma P; Updesh Singh Sachdeva M; Chhabra S; Sharma A; Das R
Infect Dis (Lond); 2016 Feb; 48(2):122-6. PubMed ID: 26431373
[TBL] [Abstract][Full Text] [Related]
10. Is routine molecular screening for common alpha-thalassaemia deletions necessary as part of an antenatal screening programme?
Sorour Y; Heppinstall S; Porter N; Wilson GA; Goodeve AC; Rees D; Wright J
J Med Screen; 2007; 14(2):60-1. PubMed ID: 17626702
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic presentation and underlying mutations in carriers of beta-thalassaemia and alpha-thalassaemia in the Danish immigrant population.
Kornblit B; Hagve TA; Taaning P; Birgens H
Scand J Clin Lab Invest; 2007; 67(1):97-104. PubMed ID: 17365987
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Thalassaemia Screening Tests in the Antenatal and Non-Antenatal Populations in Singapore.
Lee SY; Yap ES; Lee EY; Goh JH; Liu TC; Yip C
Ann Acad Med Singap; 2019 Jan; 48(1):5-15. PubMed ID: 30788489
[TBL] [Abstract][Full Text] [Related]
13. The role of discriminant functions in screening for beta-thalassaemia traits during pregnancy.
Yeo GS; Tan KH; Liu TC
Singapore Med J; 1995 Dec; 36(6):615-8. PubMed ID: 8781633
[TBL] [Abstract][Full Text] [Related]
14. Carrier screening and prenatal diagnosis of beta-thalassemia.
Maheshwari M; Arora S; Kabra M; Menon PS
Indian Pediatr; 1999 Nov; 36(11):1119-25. PubMed ID: 10745333
[No Abstract] [Full Text] [Related]
15. Thalassaemia screening and confirmation of carriers in parents.
Barrett AN; Saminathan R; Choolani M
Best Pract Res Clin Obstet Gynaecol; 2017 Feb; 39():27-40. PubMed ID: 27890718
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of high performance liquid chromatography (HPLC) pattern and prevalence of beta-thalassaemia trait among sickle cell disease patients in Lagos, Nigeria.
Adeyemo T; Ojewunmi O; Oyetunji A
Pan Afr Med J; 2014; 18():71. PubMed ID: 25400838
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of beta-thalassaemia and sickle cell traits in premarital screening in Al-Qassim, Saudi Arabia.
El-Tayeb EN; Yaqoob M; Abdur-Rahim K; Gustavson KH
Genet Couns; 2008; 19(2):211-8. PubMed ID: 18618996
[TBL] [Abstract][Full Text] [Related]
18. Screening for beta-thalassaemia carriers in Egypt: significance of the osmotic fragility test.
El-Beshlawy A; Kaddah N; Moustafa A; Mouktar G; Youssry I
East Mediterr Health J; 2007; 13(4):780-6. PubMed ID: 17955759
[TBL] [Abstract][Full Text] [Related]
19. Population Screening and Prevention Strategies for Thalassemias and other Hemoglobinopathies of Eastern India: Experience of 18,166 cases.
Chatterjee T; Chakravarty A; Chakravarty S
Hemoglobin; 2015; 39(6):384-8. PubMed ID: 26428539
[TBL] [Abstract][Full Text] [Related]
20. Mutation spectrum and erythrocyte indices characterisation of α-thalassaemia and β-thalassaemia in Sichuan women in China: a thalassaemia screening survey of 42 155 women.
Li B; Han X; Ma J; Yang D
J Clin Pathol; 2021 Mar; 74(3):182-186. PubMed ID: 32719015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
